Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06803342 · ClinicalTrials.gov registry record · Phase 2
A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Sudan Ebolavirus Vaccine in Healthy Adults
A Phase 2 study of Ebola Sudan Virus Disease, sponsored by Albert B. Sabin Vaccine Institute.
- Active
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
- 4
- Study locations
NCT06803342: Active Phase 2 study of Ebola Sudan Virus Disease, sponsored by Albert B. Sabin Vaccine Institute.
NCT06803342 is a Phase 2 study of Ebola Sudan Virus Disease that is active but no longer recruiting, run by Albert B. Sabin Vaccine Institute. The registered enrollment target is 200 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% higher). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06803342, a Phase 2 study of Ebola Sudan Virus Disease, is active but no longer recruiting, sponsored by Albert B. Sabin Vaccine Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
- 4
- Study locations
Study Summary
A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Sudan Ebolavirus Vaccine in Healthy Adults
Primary Outcome
Count and percentage of vaccinated participants who develop: - serious adverse events (SAEs), - solicited adverse events (AEs), - unsolicited AEs, - adverse event of special interest (AESI), - medically attended adverse events (MAAE), - AE at each intensity level. Estimand 1a (Primary): Count and percentage of vaccinated participants who would develop SAEs, solicited AEs, unsolicited AEs, AESI, MAAE, and AE at each intensity level will be evaluated with each treatment group. A treatment policy s
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL cAd3-Sudan Vaccine
Study Locations (4)
Arizona
- Synexus Clinical Research US, Inc. - Phoenix
Florida
- Optimal Research; LLC - Melbourne
Illinois
- Synexus Clinical Research US, Inc. - Chicago
Texas
- Synexus Clinical Research US, Inc. - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2025-06-26 |
| Est. Completion | 2027-04 |
| Phase | Phase 2 |
What the registry record for NCT06803342 still lists
NCT06803342 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% higher).
The record links to 1 condition, with Ebola Sudan Virus Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06803342 reports a single indexed study location in Arizona, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT06803342 about?
NCT06803342 is a clinical study titled "A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Sudan Ebolavirus Vaccine in Healthy Adults". A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Sudan Ebolavirus Vaccine in Healthy Adults
What is the current status of trial NCT06803342?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2025-06-26. Estimated completion is 2027-04.
What conditions does trial NCT06803342 study?
This clinical trial studies the following conditions: Ebola Sudan Virus Disease.
What interventions are being tested in trial NCT06803342?
The interventions under investigation include: Placebo (BIOLOGICAL), cAd3-Sudan Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT06803342?
This trial is sponsored by Albert B. Sabin Vaccine Institute, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06803342 being conducted?
This trial has 4 study locations across Arizona, Florida, Illinois, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06803342's enrollment target sits among peer trials
200 304th of 2000 higher than 1,652 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI